Published in Clinicoecon Outcomes Res on October 31, 2011
Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. Clinicoecon Outcomes Res (2013) 1.00
Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol (2012) 0.92
Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy. Ther Clin Risk Manag (2012) 0.89
Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines. Clinicoecon Outcomes Res (2013) 0.81
Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. Ther Clin Risk Manag (2013) 0.81
Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection. Patient Prefer Adherence (2013) 0.80
Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008. PLoS One (2012) 0.79
A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes. Clinicoecon Outcomes Res (2015) 0.76
HIV-positive patients' perceptions of care received at a selected antiretroviral therapy clinic in Vhembe district, South Africa. Afr J Prim Health Care Fam Med (2016) 0.75
Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States. PLoS One (2016) 0.75
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med (2000) 23.10
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (2008) 12.35
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (2001) 8.89
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med (2006) 8.35
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med (2001) 5.89
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr (2010) 2.85
Antiretroviral therapy and management of HIV infection. Lancet (2010) 2.84
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr (2010) 2.64
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr (2010) 2.37
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. J Acquir Immune Defic Syndr (2006) 2.17
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS (2009) 2.15
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr (2008) 2.04
One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence (2010) 1.84
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med (2006) 1.73
The cost of HIV disease in Northern Italy: the payer's perspective. J Acquir Immune Defic Syndr (2011) 1.24
Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics (2009) 1.11
Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics (2004) 1.08
Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther (2004) 1.07
Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials (2004) 1.07
Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care (2001) 0.96
A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res (2011) 0.94
Providing antiretroviral therapy for HIV infection. N Engl J Med (2001) 0.92
Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. HIV Clin Trials (2009) 0.85
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics (2010) 0.84
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics (2010) 0.81
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis (2012) 4.62
Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis (2013) 4.06
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Imported Chikungunya Infection, Italy. Emerg Infect Dis (2007) 2.08
Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy. Int J STD AIDS (2003) 1.91
Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis (2006) 1.89
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One (2011) 1.73
A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis (2007) 1.68
Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer (2005) 1.66
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther (2004) 1.65
2013 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg (2013) 1.65
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med (2015) 1.54
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS (2007) 1.48
Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet (2007) 1.47
Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet (2005) 1.45
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis (2012) 1.45
Decreasing cardiovascular risk in HIV infection between 2005 and 2011. AIDS (2014) 1.39
Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther (2013) 1.36
Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study. J Acquir Immune Defic Syndr (2006) 1.31
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. World J Emerg Surg (2011) 1.29
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica (2013) 1.26
Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J (2006) 1.25
Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant (2009) 1.25
Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) (2009) 1.24
Complicated intra-abdominal infections in Europe: a comprehensive review of the CIAO study. World J Emerg Surg (2012) 1.24
The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica (2011) 1.23
Ocular manifestations of candidemia. Clin Infect Dis (2011) 1.22
Novel beta-lactam antibiotics and inhibitor combinations. Expert Opin Investig Drugs (2008) 1.21
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther (2003) 1.19
Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother (2009) 1.17
A case of secondary syphilis presenting as optic neuritis. Neurol Sci (2010) 1.17
Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis (2007) 1.17
The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care (2010) 1.17
Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother (2012) 1.16
HIV-1 Tat protein enhances RANKL/M-CSF-mediated osteoclast differentiation. Biochem Biophys Res Commun (2010) 1.12
Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother (2010) 1.11
Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? Crit Care (2009) 1.11
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis (2006) 1.09
(1-3)-β-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections. Clin Infect Dis (2013) 1.09
Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica (2004) 1.08
Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet (2004) 1.07
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS (2005) 1.07
Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. Proc Natl Acad Sci U S A (2013) 1.07
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol (2010) 1.06
Latent tuberculosis infection and associated risk factors among undergraduate healthcare students in Italy: a cross-sectional study. BMC Infect Dis (2013) 1.06
Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy. Medicine (Baltimore) (2014) 1.05
Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. Int J Infect Dis (2010) 1.05
High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol (2010) 1.05
The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida. Virulence (2012) 1.03
Clinical evaluation of a (1,3)-beta-D-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin Vaccine Immunol (2009) 1.03
Surveillance of hospital-acquired infections: a model for settings with resource constraints. Am J Infect Control (2006) 1.03
Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia. Am J Hematol (2006) 1.03
The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis (2006) 1.02
Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. J Infect (2012) 1.02
Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis (2010) 1.02
Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database. J Antimicrob Chemother (2013) 1.02
Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis (2009) 1.02
Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur J Endocrinol (2007) 1.01
Economic evaluation of HIV treatments: the I.CO.N.A. cohort study. Health Policy (2005) 1.00
Infective endocarditis in chronic haemodialysis patients: an increasing clinical challenge. Eur Heart J (2007) 1.00
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res (2008) 1.00
Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother (2005) 1.00
Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. Clinicoecon Outcomes Res (2013) 1.00
Clinical performance of the (1,3)-β-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol (2011) 1.00
Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother (2009) 1.00
Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica (2013) 0.99
Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. AIDS (2010) 0.99
Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother (2003) 0.98
FDG PET/CT is useful for the interim evaluation of response to therapy in patients affected by haematogenous spondylodiscitis. Eur J Nucl Med Mol Imaging (2012) 0.98
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother (2005) 0.98
High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents (2010) 0.98
Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B. J Antimicrob Chemother (2004) 0.97
Pathotype and susceptibility profile of a community-acquired methicillin-resistant Staphylococcus aureus strain responsible for a case of severe pneumonia. Diagn Microbiol Infect Dis (2009) 0.97
A multicenter, randomized, double blind placebo-controlled trial of amoxicillin/clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer. Pediatr Infect Dis J (2003) 0.96
Voriconazole in clinical practice. J Chemother (2012) 0.96
Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis (2003) 0.96
Galactomannan testing might be useful for early diagnosis of fusariosis. Diagn Microbiol Infect Dis (2012) 0.96
Occurrence, presentation and treatment of candidemia. Expert Rev Clin Immunol (2012) 0.96
Current status of newer carbapenems. Curr Med Chem (2009) 0.95
Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients. Scand J Infect Dis (2011) 0.95
Combination therapy for invasive aspergillosis. Clin Infect Dis (2004) 0.95
Plasma levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. J Acquir Immune Defic Syndr (2009) 0.95
Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI). BMC Infect Dis (2014) 0.95
Screening with serum galactomannan might be associated with better outcome than symptom-triggered galactomannan testing in allogeneic HSCT recipients with invasive aspergillosis. Clin Infect Dis (2013) 0.95
Conditions associated with infections of indwelling central venous catheters in cancer patients: a summary. Br J Haematol (2003) 0.95
A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res (2011) 0.94
Cat-to-human orthopoxvirus transmission, northeastern Italy. Emerg Infect Dis (2009) 0.93
Etiology of febrile episodes in patients with acute myeloid leukemia: results from the Hema e-Chart Registry. Arch Intern Med (2011) 0.92
Prevention of infections in cardiovascular implantable electronic devices beyond the antibiotic agent. J Cardiovasc Med (Hagerstown) (2014) 0.92
Population-based surveillance of infectious endocarditis in an Italian region. Arch Intern Med (2009) 0.92
Nosocomial pulmonary infections in HIV-positive patients. Curr Opin Pulm Med (2005) 0.92